SLRN vs. DNA, IMNM, AVDL, CVAC, CDMO, NUVB, PRTA, CRON, GHRS, and BCAX
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Avid Bioservices (CDMO), Nuvation Bio (NUVB), Prothena (PRTA), Cronos Group (CRON), GH Research (GHRS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.
Acelyrin vs.
Ginkgo Bioworks (NYSE:DNA) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
In the previous week, Ginkgo Bioworks had 6 more articles in the media than Acelyrin. MarketBeat recorded 11 mentions for Ginkgo Bioworks and 5 mentions for Acelyrin. Ginkgo Bioworks' average media sentiment score of 0.36 beat Acelyrin's score of 0.18 indicating that Ginkgo Bioworks is being referred to more favorably in the media.
Ginkgo Bioworks has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
Ginkgo Bioworks currently has a consensus target price of $4.58, indicating a potential downside of 57.85%. Acelyrin has a consensus target price of $9.60, indicating a potential upside of 269.23%. Given Acelyrin's stronger consensus rating and higher possible upside, analysts clearly believe Acelyrin is more favorable than Ginkgo Bioworks.
Ginkgo Bioworks received 8 more outperform votes than Acelyrin when rated by MarketBeat users. However, 55.17% of users gave Acelyrin an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.
Acelyrin has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Acelyrin's return on equity of -44.12% beat Ginkgo Bioworks' return on equity.
Acelyrin has lower revenue, but higher earnings than Ginkgo Bioworks. Acelyrin is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Acelyrin beats Ginkgo Bioworks on 11 of the 17 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
This page (NASDAQ:SLRN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SLRN Stock Alerts